Ibio Inc (NYSE American:IBIO)

0.3219
BATS BZX Real-Time Price
As of 3:16pm ET
 -0.0225 / -6.53%
Today’s Change
0.22
Today|||52-Week Range
1.18
-41.37%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$75.3M

Company Description

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics using its FastPharming Manufacturing System. The firm operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment includes the Therapeutics unit, which is focused on oncology as well as fibrotic and infectious diseases, and the Vaccines unit, which is focused on human and animal health vaccines. The Bioprocessing segment includes Services (FastPharming, Process Development, Manufacturing, as well as Bioanalytical and other services) and Products (growth factors, lectins, and monoclonal antibodies) for research and further manufacturing uses, collectively known as Research & Bioprocess products (RBP). The company was founded by Robert B. Kay on April 15, 1993 and is headquartered in New York, NY.

Contact Information

iBio, Inc.
600 Madison Avenue
New York New York 10022
P:(302) 355-0650
Investor Relations:
(646) 274-3580

Employees

Shareholders

Mutual fund holders6.80%
Other institutional6.46%
Individual stakeholders3.65%

Top Executives

Thomas F. IsettExecutive Chairman, President & CEO
Mike JenkinsVice President-Operations
Robert M. LutzChief Financial & Business Officer
Martin B. BrennerChief Scientific Officer
James AbbeyVice President-Strategic Business Development